Trevena, Inc. (TRVN)
USD 1.27
(-0.78%)
USD 1.27
(-0.78%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 2.25 Million USD | 112.17% |
| 2022 | -18.55 Million USD | 68.98% |
| 2021 | -59.82 Million USD | 41.12% |
| 2020 | -101.59 Million USD | -439.16% |
| 2019 | -18.84 Million USD | -21.58% |
| 2018 | -15.49 Million USD | -233.34% |
| 2017 | 11.62 Million USD | 295.72% |
| 2016 | -5.93 Million USD | 79.22% |
| 2015 | -28.57 Million USD | 16.93% |
| 2014 | -34.4 Million USD | 9.38% |
| 2013 | -37.96 Million USD | -1929.73% |
| 2012 | -1.87 Million USD | 88.74% |
| 2011 | -16.61 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 20.1 Million USD | 55.16% |
| 2024 Q1 | 12.95 Million USD | 296.3% |
| 2023 FY | 3.27 Million USD | 117.62% |
| 2023 Q3 | 361 Thousand USD | 104.5% |
| 2023 Q1 | -7.84 Million USD | 57.75% |
| 2023 Q2 | -8.02 Million USD | -2.31% |
| 2023 Q4 | 3.27 Million USD | 805.82% |
| 2022 Q3 | -2.35 Million USD | -491.51% |
| 2022 Q1 | -41.75 Million USD | 30.2% |
| 2022 Q4 | -18.55 Million USD | -688.57% |
| 2022 FY | -18.55 Million USD | 68.98% |
| 2022 Q2 | 601 Thousand USD | 101.44% |
| 2021 FY | -59.82 Million USD | 41.12% |
| 2021 Q4 | -59.82 Million USD | 16.17% |
| 2021 Q1 | -90.08 Million USD | 11.33% |
| 2021 Q3 | -71.36 Million USD | 14.52% |
| 2021 Q2 | -83.48 Million USD | 7.32% |
| 2020 Q3 | -104.71 Million USD | -124.38% |
| 2020 Q1 | -19.81 Million USD | -5.14% |
| 2020 Q2 | -46.66 Million USD | -135.56% |
| 2020 Q4 | -101.59 Million USD | 2.97% |
| 2020 FY | -101.59 Million USD | -439.16% |
| 2019 Q1 | 2.91 Million USD | 118.79% |
| 2019 FY | -18.84 Million USD | -21.58% |
| 2019 Q2 | -3.86 Million USD | -232.51% |
| 2019 Q3 | -12.52 Million USD | -224.59% |
| 2019 Q4 | -18.84 Million USD | -50.4% |
| 2018 Q3 | -3.93 Million USD | -511.02% |
| 2018 FY | -15.49 Million USD | -233.34% |
| 2018 Q4 | -15.49 Million USD | -293.88% |
| 2018 Q2 | -644 Thousand USD | -109.28% |
| 2018 Q1 | 6.93 Million USD | -40.32% |
| 2017 Q2 | 13.96 Million USD | 50.63% |
| 2017 Q1 | 9.27 Million USD | 256.12% |
| 2017 FY | 11.62 Million USD | 295.72% |
| 2017 Q4 | 11.62 Million USD | 15.87% |
| 2017 Q3 | 10.03 Million USD | -28.17% |
| 2016 Q2 | -18.53 Million USD | -14.31% |
| 2016 Q1 | -16.21 Million USD | 43.25% |
| 2016 FY | -5.93 Million USD | 79.22% |
| 2016 Q4 | -5.93 Million USD | 14.38% |
| 2016 Q3 | -6.93 Million USD | 62.59% |
| 2015 Q1 | -27.4 Million USD | 20.34% |
| 2015 FY | -28.57 Million USD | 16.93% |
| 2015 Q4 | -28.57 Million USD | 23.27% |
| 2015 Q3 | -37.24 Million USD | 11.12% |
| 2015 Q2 | -41.9 Million USD | -52.91% |
| 2014 Q4 | -34.4 Million USD | 51.16% |
| 2014 Q3 | -70.43 Million USD | 13.7% |
| 2014 Q1 | -91.34 Million USD | -140.6% |
| 2014 FY | -34.4 Million USD | 9.38% |
| 2014 Q2 | -81.61 Million USD | 10.65% |
| 2013 Q1 | 6.73 Million USD | 460.27% |
| 2013 FY | -37.96 Million USD | -1929.73% |
| 2013 Q2 | -54.76 Million USD | -912.74% |
| 2013 Q4 | -37.96 Million USD | 20.88% |
| 2013 Q3 | -47.98 Million USD | 12.39% |
| 2012 FY | -1.87 Million USD | 88.74% |
| 2012 Q4 | -1.87 Million USD | 0.0% |
| 2011 FY | -16.61 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| America Great Health | 1.81 Million USD | -24.331% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | 159.187% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | -80.064% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 92.991% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 340.469% |
| Better Therapeutics, Inc. | -860 Thousand USD | 362.558% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 109.493% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -587.49% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | 50.591% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 138.777% |
| Evelo Biosciences, Inc. | 3.19 Million USD | 29.393% |
| Evolutionary Genomics, Inc. | 3.16 Million USD | 28.695% |
| Finch Therapeutics Group, Inc. | 5 Million USD | 54.858% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 98.315% |
| Innovation1 Biotech Inc. | 179.15 Thousand USD | -1160.396% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 81.7% |
| Molecular Templates, Inc. | 707 Thousand USD | -219.378% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | -415.003% |
| NexImmune, Inc. | -3.13 Million USD | 172.057% |
| Orgenesis Inc. | 21.78 Million USD | 89.635% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | 13.685% |
| Point of Care Nano-Technology, Inc. | -498.00 USD | 453513.655% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 147.934% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 1912.563% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 97.963% |
| Statera Biopharma, Inc. | 14.41 Million USD | 84.337% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 129.726% |
| Vaxxinity, Inc. | 10.13 Million USD | 77.714% |
| Vaccinex, Inc. | -1.28 Million USD | 275.311% |
| Vicapsys Life Sciences, Inc. | 344.44 Thousand USD | -555.545% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 82.944% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -3037.767% |